DCIS Dilemmas: Discussions about Ductal Carcinoma In Situ & the Research Behind It

DCIS Dilemmas: Discussions about Ductal Carcinoma In Situ & the Research Behind It

DCIS Dilemmas: Discussions about Ductal Carcinoma In Situ & the Research Behind It

DCIS Dilemmas: Discussions about Ductal Carcinoma In Situ & the Research Behind It

eBook

$2.99 

Available on Compatible NOOK Devices and the free NOOK Apps.
WANT A NOOK?  Explore Now

Related collections and offers

LEND ME® See Details

Overview

Women often think that their risk of getting Ductal Carcinoma In Situ (DCIS) or Invasive Breast Cancer (IBC) is much higher than real numbers show. This fear is often fed by new stories about research, and sometimes by their own doctors. Many doctors and researchers say that DCIS is not Invasive Breast Cancer (IBC) because it stays in the breast duct. HOWEVER... DCIS is also called Stage 0 breast cancer, and is treated as if it were IBC.

There are many dilemmas about DCIS, and this book tries to clear them up. We know how easy it is to end up more confused after looking at different websites, books, and research results. We present a new way to approach DCIS that combines the latest research with practical information. Even though we state things plainly, many scientific resources and references were used to make sure this book is accurate. Please be aware that those resources may use older language that we are learning is not accurate for DCIS. For example, DCIS lesions do not have the ability to "recur," even though this term is commonly used by many scientists and doctors.

You will learn about DCIS and how it fits into breast diseases, including breast cancer. The process of getting diagnosed is also explained, as are the different types of treatments that are commonly given for DCIS. Risks are also explained clearly. This includes the risk of being diagnosed with DCIS, as well as the risk of getting another DCIS or a future Invasive Breast Cancer. This book also highlights the various kinds of ongoing research for DCIS. A list of terms, and additional resources and references are also included to help you find more detailed information. We hope this book offers useful information to help you make decisions about DCIS, and look forward to hearing how you use it!

Product Details

BN ID: 2940151131681
Publisher: First Edition Design Publishing
Publication date: 10/14/2015
Sold by: Barnes & Noble
Format: eBook
File size: 3 MB

About the Author

Deborah Collyar (1st author):
Deborah Collyar was breaking glass ceilings in a computer company when she found a lump at age 32. A mastectomy, chemotherapy, radiation, and chemo-induced menopause produced a new outlook on career and life, especially after delivering a healthy baby in 1993. Ductal Carcinoma in Situ (DCIS), another breast cancer, and husband Bob's lung cancer sent them blazing new trails by injecting patients directly into the research process, from policies, idea generation and grant proposals, to development, clinical trials, and delivering 'better results to people faster.' As President of Patient Advocates In Research (PAIR), Deborah serves on countless committees and boards with researchers worldwide, travels constantly, speaks to large and small professional and public groups, and helps patients at all stages of their journey. She functions as an individual, as 'the patient voice,' as group leader, and as an acknowledged peer in the research community. By creating a career where none existed, she helps others play a role of their choosing while not losing focus on the issues that the cancer patient deals with every day.

Philippe Gascard (2nd author):
Over the last 30 years, Dr. Philippe Gascard has built a solid background in protein and lipid chemistry, molecular biology, cell biology, systems biology and epigenetics. Over the past 10 years, Dr. Gascard has gained extensive expertise in breast cancer biology with an emphasis on epigenetics, biomarker discovery and multiplex immunohistochemistry. An active participant of the Integrative Cancer Biology Program (ICBP), he was the Director of the Central Pathology Laboratory for the UCSF Roadmap Epigenetics Mapping Consortium (REMC) from 2008 to 2014. As researcher and project manager in Dr. Tlsty's laboratory since 2008, he has been closely involved in the writing and scientific conceptualization of multiple grant applications, including a recently funded award aimed at identifying new biomarkers for prediction of outcome in patients diagnosed with DCIS.

Thea Tlsty (3rd author):
Dr. Thea Tlsty has over 25 years of experience studying human cells and the earliest steps of malignancy. The model systems she developed contribute to clinical utility by identifying molecular stromal-epithelial interactions that facilitate tumor progression in the breast and prostate.
From the B&N Reads Blog

Customer Reviews